Search

Your search keyword '"Merchant, Sanjay"' showing total 132 results
Start Over Author "Merchant, Sanjay"
132 results on '"Merchant, Sanjay"'

1. Comparative efficacy of pembrolizumab with carboplatin and paclitaxel as first-line (1L) therapy in recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC): A network meta-analysis (NMA) with matching-adjusted indirect comparison (MAIC).

Author

Zheng, Dandan, primary, Mojebi, Ali, additional, Black, Christopher M., additional, Giezek, Hilde, additional, Naicker, Niroshini, additional, Vanetta, Chiara, additional, Keeping, Sam, additional, Merchant, Sanjay, additional, and Dzienis, Marcin Radoslaw, additional

Published
2024
Full Text
View/download PDF

6. 1464. Real-World (RW) Utilization Pattern of Letermovir in Adult Cytomegalovirus Seropositive Allogeneic Hematopoietic Stem Cell Transplant (HCT) Recipients: A Multicenter Retrospective Cohort Study from the European Society for Blood and Marrow Transplantation (EBMT) Registry

Author

Styczynski, Jan, primary, Tridello, Gloria, additional, Knelange, Nina, additional, Wendel, Lotus, additional, Xhaard, Alienor, additional, Cutini, Ilaria, additional, Chiusolo, Patrizia, additional, Franke, Georg-Nikolaus, additional, Kraus, Sabina, additional, Raval, Amit D, additional, Merchant, Sanjay, additional, and de la Camara, Rafael, additional

Published
2022
Full Text
View/download PDF

9. Additional file 1 of Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis

Author

Raman, Gowri, Avendano, Esther E., Chan, Jeffrey, Merchant, Sanjay, and Puzniak, Laura

Abstract

Table S1. Search Strategy. Table S2. Patient–related Multivariate Risk Factors of Acquistion of MDR P. aeruginosa. Table S3. Antibiotic Treatment–related Multivariate Risk Factors of Acquistion of MDR P. aeruginosa. Table S4. Other Treatment–related Multivariate Risk Factors of Acquistion of MDR and XDR P. aeruginosa. Table S5. Hospital–related Multivariate Risk Factors of Acquistion of MDR and XDR P. aeruginosa. Table S6. Patient–related Multivariate Risk Factors of Acquistion of Carbapenem-resistant P. aeruginosa. Table S7. Antibiotic Treatment–related Multivariate Risk Factors of Acquistion of Carbapenem-resistant P. aeruginosa. Table S8. Other Treatment–related Multivariate Risk Factors of Acquistion of Carbapenem-resistant P. aeruginosa. Table S9. Hospital–related Multivariate Risk Factors of Acquistion of Carbapenem-resistant P. aeruginosa. Table S10. Multivariate Risk Factors of Acquistion of Resistant P. aeruginosa. Figure S1. Meta-analysis of Risk Factors for Carbapenem versus Susceptible P. aeruginosa Acquisition. Figure S2. Meta-analysis of Prior Use of Carbapenem as a Risk Factor for Carbapenem versus Susceptible P. aeruginosa Acquisition. Figure S3. Meta-analysis of Prior Use of Fluoroquinolones as a Risk Factor for Quinolone-resistant versus Susceptible P. aeruginosa Acquisition. (DOCX 182 kb)

Published
2023
Full Text
View/download PDF

17. Additional file 1 of Pseudomonas infections among hospitalized adults in Latin America: a systematic review and meta-analysis

Author

Leon, Alfredo Ponce De, Merchant, Sanjay, Raman, Gowri, Avendano, Esther, Chan, Jeffrey, Hernandez, Griselda Tepichin, and Sarpong, Eric

Abstract

Additional file 1 Table S1. Search Strategy comparing AIAT vs. IIAT. Table S2. Search Strategy for acquisition of resistant P. aeruginosa. Table S3. Risk of Bias Assessment for AIAT vs. IIAT Studies. Table S4. Risk of Bias Assessment for Risk Factors Studies. Table S5. Risk Factors Predicting Acquisition of Resistant P. aeruginosa. Table S6. GRADE Overall Strength of Evidence for Relevant Outcomes.

Published
2020
Full Text
View/download PDF

26. Cost‐effectiveness analysis of cytomegalovirus prophylaxis in allogeneic hematopoietic cell transplant recipients from a US payer perspective.

Author

Alsumali, Adnan, Chemaly, Roy F., Graham, Jonathan, Jiang, Yiling, Merchant, Sanjay, Miles, LaStella, Schelfhout, Jonathan, Yang, Joe, and Tang, Yuexin

Subjects
CYTOMEGALOVIRUS diseases, CLINICAL trial registries, QUALITY-adjusted life years, CYTOMEGALOVIRUSES, PREVENTIVE medicine, ANTIBIOTIC prophylaxis, HEMATOPOIETIC stem cell transplantation
Abstract

To evaluate the cost‐effectiveness of letermovir versus no prophylaxis for the prevention of cytomegalovirus infection and disease in adult cytomegalovirus‐seropositive allogeneic hematopoietic cell transplantation (allo‐HCT) recipients. A decision model for 100 patients was developed to estimate the probabilities of cytomegalovirus infection, cytomegalovirus disease, various other complications, and death in patients receiving letermovir versus no prophylaxis. The probabilities of clinical outcomes were based on the pivotal phase 3 trial of letermovir use for cytomegalovirus prophylaxis versus placebo in adult cytomegalovirus‐seropositive recipients of an allo‐HCT. Costs of prophylaxis with letermovir and of each clinical outcome were derived from published sources or the trial clinical study reports. Incremental cost‐effectiveness ratios (ICERs) in terms of cost per quality‐adjusted life year (QALY) gained were used in the model. One‐way and probabilistic sensitivity analyses were conducted to explore uncertainty around the base‐case analysis. In this model, the use of letermovir prophylaxis would lead to an increase of QALYs (619) and direct medical cost ($1 733 794) compared with no prophylaxis (578 QALYs; $710 300) in cytomegalovirus‐seropositive recipients of an allo‐HCT. Letermovir use for cytomegalovirus prophylaxis was a cost‐effective option versus no prophylaxis with base‐case analysis ICER $25 046/QALY gained. One‐way sensitivity analysis showed the most influential parameter was mortality rate. The probabilistic sensitivity analysis showed a 92% probability of letermovir producing an ICER below the commonly accepted willingness‐to‐pay threshold of $100 000/QALY gained. Based on this model, letermovir use for cytomegalovirus prophylaxis was a cost‐effective option in adult cytomegalovirus‐seropositive recipients of an allo‐HCT. Highlights: letermovir prophylaxis lead to better healthcare outcomes and higher direct medical costs compared with no prophylaxis.letermovir prophylaxis is cost‐effective option versus no prophylaxis in adult cytomegalovirus‐seropositive recipients of an allo‐HCT, with incremental cost‐effectiveness ratios below $30,000 per quality‐adjusted life‐year gained. [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

27. Additional file 1: of Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis

Author

Raman, Gowri, Avendano, Esther E., Chan, Jeffrey, Merchant, Sanjay, and Puzniak, Laura

Abstract

Table S1. Search Strategy. Table S2. Patient–related Multivariate Risk Factors of Acquistion of MDR P. aeruginosa. Table S3. Antibiotic Treatment–related Multivariate Risk Factors of Acquistion of MDR P. aeruginosa. Table S4. Other Treatment–related Multivariate Risk Factors of Acquistion of MDR and XDR P. aeruginosa. Table S5. Hospital–related Multivariate Risk Factors of Acquistion of MDR and XDR P. aeruginosa. Table S6. Patient–related Multivariate Risk Factors of Acquistion of Carbapenem-resistant P. aeruginosa. Table S7. Antibiotic Treatment–related Multivariate Risk Factors of Acquistion of Carbapenem-resistant P. aeruginosa. Table S8. Other Treatment–related Multivariate Risk Factors of Acquistion of Carbapenem-resistant P. aeruginosa. Table S9. Hospital–related Multivariate Risk Factors of Acquistion of Carbapenem-resistant P. aeruginosa. Table S10. Multivariate Risk Factors of Acquistion of Resistant P. aeruginosa. Figure S1. Meta-analysis of Risk Factors for Carbapenem versus Susceptible P. aeruginosa Acquisition. Figure S2. Meta-analysis of Prior Use of Carbapenem as a Risk Factor for Carbapenem versus Susceptible P. aeruginosa Acquisition. Figure S3. Meta-analysis of Prior Use of Fluoroquinolones as a Risk Factor for Quinolone-resistant versus Susceptible P. aeruginosa Acquisition. (DOCX 182 kb)

Published
2018
Full Text
View/download PDF

29. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitro surveillance of bacterial isolates in the UK

Author

Vimalanand Prabhu, Foo, Jason, Harblas Ahir, Sarpong, Eric, and Merchant, Sanjay

Subjects
polycyclic compounds
Abstract

Aims: An increase in the prevalence of antimicrobial resistance among gram-negative pathogens has been noted recently.[1] A challenge in empiric treatment of complicated intra-abdominal infection (cIAI) is identifying initial appropriate antibiotic therapy, which is associated with reduced length of stay and mortality compared with inappropriate therapy. The objective of this study was to assess the cost-effectiveness of ceftolozane/tazobactam+metronidazole compared with piperacillin/tazobactam (commonly used in this indication) in the treatment of patients with cIAI in United Kingdom (UK) hospitals. Methods: A decision-analytic Monte Carlo simulation model was used to compare costs (antibiotic and hospitalization costs) and quality-adjusted life years (QALYs) of patients infected with gram-negative cIAI and treated empirically with either ceftolozane/tazobactam+metronidazole or piperacillin/tazobactam. Bacterial isolates were randomly drawn from the Program to Assess Ceftolozane/Tazobactam Susceptibility (PACTS) database, a surveillance database of non-duplicate bacterial isolates collected from patients in the UK infected with gram-negative pathogens. Susceptibility to initial empiric therapy was based on the measured susceptibilities reported in the PACTS database. Results: Ceftolozane/tazobactam+metronidazole was cost-effective when compared with piperacillin/tazobactam with an incremental cost-effectiveness ratio (ICER) of £4,350/QALY and 0.36 hospitalisation days/patient saved. Costs in the ceftolozane/tazobactam+metronidazole arm were £2,576/patient compared with £2,168/patient in the piperacillin/tazobactam arm. The ceftolozane/tazobactam+metronidazole arm experienced a greater number of QALYs than the piperacillin/tazobactam arm (14.31/patient vs. 14.21/patient, respectively). Ceftolozane/tazobactam+metronidazole remained cost-effective in one-way sensitivity and probabilistic sensitivity analyses. Conclusions: Economic models can help to identify the appropriate choice of empiric therapy for the treatment of cIAI. Results indicated that empiric use of ceftolozane/tazobactam+metronidazole is cost-effective versus piperacillin/tazobactam in UK patients with cIAI at risk of resistant infection. This will be valuable to commissioners and clinicians to aid decision-making on the targeting of resources for appropriate antibiotic therapy under the premise of antimicrobial stewardship.

Published
2017
Full Text
View/download PDF

43. The Direct Medical Costs of [[Alpha].sub.1]-Antitrypsin Deficiency(*)

Author

Mullins, C. Daniel, Huang, Xingyue, Merchant, Sanjay, and Stoller, James K.

Subjects
Emphysema, Pulmonary -- Drug therapy -- Research, Medical economics -- Research -- Economic aspects, Intravenous therapy -- Economic aspects -- Research, Health, Drug therapy, Economic aspects, Research
Abstract

Background: For individuals with emphysema because of severe [[Alpha].sub.1]-antitrypsin deficiency, specific therapy called IV augmentation therapy has been available since 1989. Such therapy consists of IV infusion of pooled human [...]

Published
2001

45. Risk factors for Pseudomonas aeruginosainfections in Asia-Pacific and consequences of inappropriate initial antimicrobial therapy: A systematic literature review and meta-analysis

Author

Merchant, Sanjay, Proudfoot, Emma M., Quadri, Hafsa N., McElroy, Heather J., Wright, William R., Gupta, Ankur, and Sarpong, Eric M.

Abstract

•Asia-Pacific has high rates of antimicrobial resistance in Pseudomonas aeruginosa.•Initial appropriate antimicrobial therapy is associated with lower mortality than inappropriate therapy.•Risk factors for serious infection include previous exposure to antimicrobials.•Access to newer and appropriate antimicrobials is vital in the Asia-Pacific region.

Published
2018
Full Text
View/download PDF

47. Cost-effectiveness of ceftolozane/tazobactam plus metronidazole compared with piperacillin/tazobactam as empiric therapy for the treatment of complicated intra-abdominal infections based on the in-vitrosurveillance of bacterial isolates in the UK

Author

Prabhu, Vimalanand, Foo, Jason, Ahir, Harblas, Sarpong, Eric, and Merchant, Sanjay

Abstract

AbstractAims:An increase in the prevalence of antimicrobial resistance among gram-negative pathogens has been noted recently. A challenge in empiric treatment of complicated intra-abdominal infection (cIAI) is identifying initial appropriate antibiotic therapy, which is associated with reduced length of stay and mortality compared with inappropriate therapy. The objective of this study was to assess the cost-effectiveness of ceftolozane/tazobactam + metronidazole compared with piperacillin/tazobactam (commonly used in this indication) in the treatment of patients with cIAI in UK hospitals.Methods:A decision-analytic Monte Carlo simulation model was used to compare costs (antibiotic and hospitalization costs) and quality-adjusted life years (QALYs) of patients infected with gram-negative cIAI and treated empirically with either ceftolozane/tazobactam + metronidazole or piperacillin/tazobactam. Bacterial isolates were randomly drawn from the Program to Assess Ceftolozane/Tazobactam Susceptibility (PACTS) database, a surveillance database of non-duplicate bacterial isolates collected from patients in the UK infected with gram-negative pathogens. Susceptibility to initial empiric therapy was based on the measured susceptibilities reported in the PACTS database.Results:Ceftolozane/tazobactam + metronidazole was cost-effective when compared with piperacillin/tazobactam, with an incremental cost-effectiveness ratio (ICER) of £4,350/QALY and 0.36 hospitalization days/patient saved. Costs in the ceftolozane/tazobactam + metronidazole arm were £2,576/patient, compared with £2,168/patient in the piperacillin/tazobactam arm. The ceftolozane/tazobactam + metronidazole arm experienced a greater number of QALYs than the piperacillin/tazobactam arm (14.31/patient vs 14.21/patient, respectively). Ceftolozane/tazobactam + metronidazole remained cost-effective in one-way sensitivity and probabilistic sensitivity analyses.Conclusions:Economic models can help to identify the appropriate choice of empiric therapy for the treatment of cIAI. Results indicated that empiric use of ceftolozane/tazobactam + metronidazole is cost-effective vs piperacillin/tazobactam in UK patients with cIAI at risk of resistant infection. This will be valuable to commissioners and clinicians to aid decision-making on the targeting of resources for appropriate antibiotic therapy under the premise of antimicrobial stewardship.

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results